• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2021.16061

Predictors of adverse cardiovascular events in patients with primary percutaneous coronary intervention for myocardial infarction

[Original research] [Internal diseases]
Natalia Kompanets; Larisa Limareva; Alexander Shpigel; Yuri Schukin;

In 88 patients (mean age 55.4±7.6 years) who underwent primary percutaneous coronary intervention (PCI) for myocardial infarction (MI), predictors of adverse cardiovascular events were assessed over a 1-year fol-low-up period. The parameters of echocardiography and coronary angi-ography were evaluated, the concentrations of the N-terminal fragment of brain natriuretic peptide (NT-proBNP) and soluble receptor of stimulating growth factor expressed by gene 2 (sST2) were determined. In patients, the worst prognosis was associated with intermediate or decreased ejection frac-tion (EF) (odds ratio (OR)=4.4, p=0.009), left ventricular (LV) aneurysm (OR=33, p=0.002), high NT-proBNP concentrations (OR=1.003, p<0.001), sST2 (OR=1.183, p<0.001) and Syntax scores (OR=1.062, p=0.011).

Download

References:
1. Palmerini T., Biondi-Zoccai G., Della Riva D., Mariani A., Sabaté M. [et al.]. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J. Am. Coll. Cardiol. 2013;62(6):496-504.
https://doi.org/10.1016/j.jacc.2013.05.022
2. Minicucci M. F., Azevedo P. S., Polegato B. F., Paiva S. A., Zornoff L. A. Heart failure after myocardial infarction: clinical implications and treatment. Clin. Cardiol. 2011;34(7):410- 414.
https://doi.org/10.1002/clc.20922
3. Giustino G., Redfors B., Brener S. J., Kirtane A. J., Généreux P. [et al.]. Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial. Eur. Heart J. Acute Cardiovasc. Care. 2018;7(4):339-347.
https://doi.org/10.1177/2048872617719649
4. Chen J., Hsieh A. F.-C., Dharmarajan K., Masoudi F. A., Krumholz H. M. National trends in heart failure hospitalization after acute myocardial infarction for medicare beneficiaries: 1998-2010. Circulation. 2013;128(24): 2577-2584.
https://doi.org/10.1161/CIRCULATIONAHA.113.003668
5. Rusnak J., Fastner C., Behnes M., Mashayekhi K., Borggrefe M., Akin I. Biomarkers in stable coronary artery disease. Curr. Pharm. Biotechnol. 2017;18(6):456-471.
https://doi.org/10.2174/1389201018666170630120805
6. Medvedeva E. A., Surkova E. A., Limareva L. V., Shchukin Yu. V. Molecular biomarkers for diagnostics, risk stratification and prediction of chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal. – Russian journal of cardiology. 2016;21(8):86-91. (In Russ.).
https://doi.org/10.15829/1560-4071-2016-8-86-91
7. Chow S. L., Maisel A. S., Anand I., Bozkurt B., De Boer R. A. [et al.]. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054-e1091.
https://doi.org/10.1161/CIR.0000000000000490
8. Slatova L. N., Fedorina T. A., Bormotov A. V., Samychin M. Yu., Buklesheva I. M. Morphological characteristics of coronary and carotid atherosclerotic plaques in patients with myocardial infarction. Nauka i innovatsii v meditsine. – Science and innovation in medicine. 2017;2(6):15-19. (In Russ.).
9. Du X. Post-infarct cardiac injury, protection and repair: roles of non-cardiomyocyte multicellular and acellular components. Sci. China Life Sci. 2018;61(3):266-276.
https://doi.org/10.1007/s11427-017-9223-x
10. Alonso N., Lupón J., Barallat J., de Antonio M., Domingo M. [et al.]. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovasc. Diabetol. 2016;15(1):151.
https://doi.org/10.1186/s12933-016-0470-x
11. Skvortsov A. A., Protasov V. N., Narusov O. Yu., Koshkina D. E., Nasonova S. N. [et al.]. Soluble suppression of tumorogenicity 2 increases opportunities for risk stratification after acute heart failure decompensation. Kardiologiya. – Cardiology. 2017;57(1):48-58. (In Russ.).
https://doi.org/10.18565/cardio.2017.1.48-58
12. Lupón J., de Antonio M., Vila J., Peñafiel J., Galán A. [et al.]. Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS One. 2014;9(1):e85466.
https://doi.org/10.1371/journal.pone.0085466
13. Kopeva K. V., Grakova E. V., Teplyakov A. T. New biomarkers of heart failure: diagnostic and prognostic value of NT-proBNP and interleukin receptor family member ST2. Kompleksnyye problemy serdechno-sosudistykh zabolevaniy. – Complex problems of cardiovascular diseases. 2018;7(1):94-101. (In Russ.).
https://doi.org/10.17802/2306-1278-2018-7-1-94-101
14. Dyleva Yu. A., Gruzdeva O. V., Akbasheva O. E., Uchasova E. G., Fedorova N. V. [et al.]. Significance of stimulating growth factor ST2 and NT-proBNP in assessment of postinfarction remodeling of the heart. Rossiyskiy kardiologicheskiy zhurnal. – Russian journal of cardiology. 2015;128(12):63-71. (In Russ.).
https://doi.org/10.15829/1560-4071-2015-12-63-71
15. Ahluwalia N., Blacher J., Szabo de Edelenyi F., Faure P., Julia C. [et al.]. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis. 2013;228(2):478-484.
https://doi.org/10.1016/j.atherosclerosis.2013.03.017
16. Yu J., Oh P. C., Kim M., Moon J., Park Y. M. [et al.]. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. PLoS One. 2017;12(8):e0182829.
https://doi.org/10.1371/journal.pone.0182829
17. Ruda M. Ya., Averkov O. V., Panchenko E. P., Yavelov I. S. Guideline for the management of patients with non-ST-elevation acute coronary syndromes (PART 1). Kardiologicheskiy vestnik. – Cardiological Bulletin. 2017;XIV(3):3-28 (In Russ.).
18. Fomin V. V., Svistunov A. A., Napalkov D. A., Sokolova A. A., Skripka A. I. [et al.]. The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice. Terapevticheskiy arkhiv. – Therapeutic archive. 2017;89(12):4-9. (In Russ.).
https://doi.org/10.17116/terarkh201789124-9
19. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal. – Russian journal of cardiology. 2017;141(1):7-81. (In Russ.).
https://doi.org/10.15829/1560-4071-2017-1-7-81
20. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). 2014 ESC/EACTS Guidelines on myocardial revascularization. Rossiyskiy kardiologicheskiy zhurnal. – Russian journal of cardiology. 2015;118(2):5-81. (In Russ.).
https://doi.org/10.15829/1560-4071-2015-02-5-81
21. Piper S. E., Sherwood R. A., Amin-Youssef G. F., Shah A. M., McDonagh T. A. Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. Int. J. Cardiol. 2015;178:284-291.
https://doi.org/10.1016/j.ijcard.2014.11.097
22. Jenkins W. S., Roger V. L., Jaffe A. S., Weston S. A., Abou Ezzeddine O. F. [et al.]. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am. J. Med. 2017;130(9):1112.e9-1112.e15.
https://doi.org/10.1016/j.amjmed.2017.02.034
23. Wang Y.-P., Wang J.-H., Wang X.-L., Liu J.-Y., Jiang F.-Y. [et al.]. Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention. J. Cell. Mol. Med. 2017;21(11):2677-2684.
https://doi.org/10.1111/jcmm.13183
24. Gerber Y., Weston S. A., Enriquez Sarano M., Jaffe A. S., Manemann S. M. [et al.]. Contemporary risk stratification after myocardial infarction in the community: performance of scores and incremental value of soluble suppression of tumorigenicity-2. J. Am. Heart Assoc. 2017;6(10):e005958.
https://doi.org/10.1161/JAHA.117.005958
25. Minamisawa M., Motoki H., Izawa A., Kashima Y., Hioki H. [et al.]. Comparison of inflammatory biomarkers in outpatients with prior myocardial infarction. Int. Heart J.
2016;57(1):11-17. https://doi.org/10.1536/ihj.15-197

Keywords: myocardial infarction, prognosis, ST2, NT-proBNP